239 related articles for article (PubMed ID: 2468052)
1. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
Longman SD; Clapham JC; Wilson C; Hamilton TC
J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil.
Wilson C; Coldwell MC; Howlett DR; Cooper SM; Hamilton TC
Eur J Pharmacol; 1988 Aug; 152(3):331-9. PubMed ID: 2851450
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
[TBL] [Abstract][Full Text] [Related]
4. Effects of pinacidil, cromakalim, and nicorandil on potassium currents of rat basilar artery smooth muscle.
Zhang H; Stockbridge N; Weir B
Adv Exp Med Biol; 1991; 304():531-41. PubMed ID: 1839488
[No Abstract] [Full Text] [Related]
5. The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle.
Yanagisawa T; Hashimoto H; Taira N
Br J Pharmacol; 1988 Oct; 95(2):393-8. PubMed ID: 2852521
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
Atwal KS
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S12-7. PubMed ID: 7898103
[TBL] [Abstract][Full Text] [Related]
7. [Advance in pharmacology of potassium channels in cardiovascular system and their clinical use].
Wu Y; Fang D
Zhonghua Yi Xue Za Zhi; 1992 Mar; 72(3):180-3. PubMed ID: 1319810
[No Abstract] [Full Text] [Related]
8. The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers.
McPherson GA; Stork AP
Br J Pharmacol; 1992 Jan; 105(1):51-8. PubMed ID: 1534504
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil.
Yanagisawa T; Teshigawara T; Taira N
Br J Pharmacol; 1990 Sep; 101(1):157-65. PubMed ID: 2149290
[TBL] [Abstract][Full Text] [Related]
10. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
Nielsen-Kudsk JE
Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
[TBL] [Abstract][Full Text] [Related]
11. Analysis of cromakalim-, pinacidil-, and nicorandil-induced relaxation of the 5-hydroxytryptamine precontracted rat isolated basilar artery.
Ksoll E; Parsons AA; Mackert JR; Schilling L; Wahl M
Naunyn Schmiedebergs Arch Pharmacol; 1991 Apr; 343(4):377-83. PubMed ID: 1830131
[TBL] [Abstract][Full Text] [Related]
12. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential.
Longman SD; Hamilton TC
Med Res Rev; 1992 Mar; 12(2):73-148. PubMed ID: 1535674
[No Abstract] [Full Text] [Related]
13. Comparison of the in vitro effects of K+ channel modulators on detrusor and portal vein strips from guinea pigs.
Zografos P; Li JH; Kau ST
Pharmacology; 1992; 45(4):216-30. PubMed ID: 1438528
[TBL] [Abstract][Full Text] [Related]
14. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
Satoh K
Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
[TBL] [Abstract][Full Text] [Related]
15. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
16. Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery.
Eltze M
Eur J Pharmacol; 1989 Jun; 165(2-3):231-9. PubMed ID: 2528466
[TBL] [Abstract][Full Text] [Related]
17. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
Cavero I; Pratz J; Mondot S
Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
[TBL] [Abstract][Full Text] [Related]
18. Potassium channel opening properties of a novel compound, NIP-121, cromakalim and nicorandil in rat aorta and portal vein.
Masuda Y; Arakawa C; Yamashita T; Miyajima M; Shigenobu K; Kasuya Y; Tanaka S
Eur J Pharmacol; 1991 Apr; 195(3):323-31. PubMed ID: 1831135
[TBL] [Abstract][Full Text] [Related]
19. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
20. [The vasospasmolytic effects of nicorandil, cromakalim and pinacidil on 3,4-diaminopyridine-induced phasic contractions in canine coronary arteries as an experimental vasospasm model].
Kamijo T; Tomaru T; Miwa A; Nakamura F; Kido H; Sugimoto T; Uchida Y
Nihon Yakurigaku Zasshi; 1992 Oct; 100(4):317-27. PubMed ID: 1446882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
